Profil de fragilité excluant l'intensification de 1L systémique dans le HCC: ECOG ≥3, OU (âge ≥75 + P...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | RF-HCC-FRAILTY-AGE |
|---|---|
| Type | Signal d’alerte |
| État | reviewed 2026-04-26 | pending_clinical_signoff |
| Maladies | DIS-HCC |
| Sources | SRC-AASLD-HCC-2023 SRC-NCCN-HCC-2025 |
Origine du drapeau rouge
| Définition | Frailty profile precluding intensified 1L systemic in HCC: ECOG ≥3, OR (age ≥75 + Child-Pugh B7 + sarcopenia), OR composite (Karnofsky <70 + active hepatic encephalopathy + albumin <2.8). Triggers BSC discussion + palliative-care referral; sorafenib reduced-dose (200 mg BID) acceptable for selected CP-A frail patients. |
|---|---|
| Direction clinique | désescalade |
| Catégorie | âge de fragilité |
| Algorithme de décalage | ALGO-HCC-SYSTEMIC-1L |
Logique de déclenchement
{
"any_of": [
{
"comparator": ">=",
"finding": "ecog",
"threshold": 3
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 75
},
{
"finding": "child_pugh_class",
"value": "B"
},
{
"finding": "sarcopenia_present",
"value": true
}
]
}
],
"type": "composite_score"
}
Notes
IMbrave150 + HIMALAYA both required ECOG ≤1 — frail elderly excluded from pivotal trials. Real-world: sorafenib 200 mg BID start with cautious escalation; lenvatinib body-weight-based dosing (8 mg if ≤60 kg). Best supportive care + palliative referral when life expectancy <3 months.
Utilisé par
Algorithmes
ALGO-HCC-SYSTEMIC-1L- ALGO-HCC-SYSTEMIC-1L
Indication
IND-HCC-SYSTEMIC-2L-CABOZANTINIB- IND-HCC-SYSTEMIC-2L-CABOZANTINIBIND-HCC-SYSTEMIC-2L-RAMUCIRUMAB- IND-HCC-SYSTEMIC-2L-RAMUCIRUMABIND-HCC-SYSTEMIC-2L-REGORAFENIB- IND-HCC-SYSTEMIC-2L-REGORAFENIB